Skip to content

To know effect of astanga ghrita nasya and astanga granules in low average intelligence in 5th standard children

A Clinical study to evaluate efficacy ofastanga ghrita nasyaand astanga granules internally in 5th standard of low average intelligence

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/083208
Enrollment
20
Registered
2025-03-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F70- Mild intellectual disabilities

Interventions

None listed

Sponsors

Dr Inchara P
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. The children of either gender studying in 5thstandard fulfilling the diagnostic criteria. 2. Children whose parents are willing to participate the in the study after giving informed parent consent and oral assent by child.

Exclusion criteria

Exclusion criteria: 1.Children with learning disabilities or any other neuro-cognitive dysfunction like ADHD,Autism.

Design outcomes

Primary

MeasureTime frame
To evaluate the combined effect of astanga ghrita nasya and astanga granules orally in 5th standard children of low average 1qTimepoint: Initially screening is done with Draw man test then assessment on 1st day with binet kamath scale of intelligence and reassessment is done on 45th day after treatment using binet kamath scale of intelligence

Secondary

MeasureTime frame
To evaluate the combined effect of astanga ghrita nasya and oral administration of astanga granules in 5th standard children with low average IQ.Timepoint: Assesment 1st day before treatment and 45days after treatment

Countries

India

Contacts

Public ContactDr Nayan Kumar S

Rajiv Gandhi University of Healthcare Science, Bangalore

drnayankumar@sdmcahhassan.org8197589426

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026